Patents by Inventor Peter Claude

Peter Claude has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5856466
    Abstract: Processes for preparing 2'-O-alkylated guanosine, uridine, cytidine, and 2,6-diaminopurine 3'-O-phosphoramidites include the steps of alkylating nucleoside precursors, adding suitable blocking groups and phosphitylating. For the guanosine 2'-O-alkylated 3'-O-phosphoramidites, alkylation is effected on 2,6-diamino-9-(.beta.-D-ribofuranosyl)purine followed by deamination. For uridine 2'-O-alkylated 3'-O-phosphoramidites, alkylation is effect on a dialkyl stannylene derivative of uridine. For cytidine 2'-O-alkylated 3'-O-phosphoramidites, alkylation is effected directly on cytidine. Alkylation is effected directly upon 2,6-diaminopurine.
    Type: Grant
    Filed: July 7, 1997
    Date of Patent: January 5, 1999
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Phillip Dan Cook, Daniel Peter Claude McGee, Charles John Guinosso
  • Patent number: 5751595
    Abstract: A method for verifying that an integrated circuit design tool kit has not been modified in an unauthorized manner is accomplished by providing a verification procedure that, when an executable subrule of the tool kit has been selected to be part of the rule system, the executable subrule reads a table of time stamps. This table of time stamps and a key are provided, as representative data, to an authentication subrule by the executable subrule. The executable subrule and the authentication subrule perform an authentication check algorithm upon the representative data to produce remotely and locally checked data respectively. The executable subrule then provides the locally checked data to the authentication subrule which compares the locally checked data with the remotely checked data. When a match occurs between the data, the authentication subrule indicates that the executable subrule has not been modified in an unauthorized manner.
    Type: Grant
    Filed: March 14, 1996
    Date of Patent: May 12, 1998
    Assignee: International Business Machines Corporation
    Inventors: Harry John Beatty, III, Peter Claude Elmendorf, Jeannie Harrigan Panner, Bijan Salimi, Lansing Dunn Pickup
  • Patent number: 5748489
    Abstract: In order to efficiently execute a complex task within a computer system, the task is partitioned into a plurality of entities. A master process and a slave process are started for each entity. The master processes schedule operations to be performed, while the slave processes perform the operations. One slave process is coupled to one or more other slave processes because of path interconnections between the entities. Communication is established between any coupled slave processes such that one slave process may directly communicate with another slave process without involving the master processes. The master and slave processes execute in parallel on a plurality of processors.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: May 5, 1998
    Assignee: International Business Machines Corporation
    Inventors: Harry John Beatty, Peter Claude Elmendorf, Roland Roberto Gillis, Ira Pramanick
  • Patent number: 5646265
    Abstract: 2'-O-alkylated guanosine, uridine, cytidine, and 2,6-diaminopurine 3'-O-phosphoramidites are prepared by alkylating nucleoside precursors, adding suitable blocking groups and phosphitylating. Alkylation is effected on 2,6-diamino-9-(.beta.-D-ribofuranosyl)purine followed by deamination to prepare guanosine 2'-O-alkylated 3'-O-phosphormidites. Alkylation is effected on a dialkyl stannylene derivative of uridine to prepare uridine 2'-O-alkylated 3'-O-phosphormidites. Alkylation is effected directly on cytidine to prepare cytidine 2'-O-alkylated 3'-O-phosphormidites. Alkylation is effected directly on 2,6-diaminopurine to prepare 2,6-diaminopurine 2'-O-alkylated 3'-O-phosphormidites.
    Type: Grant
    Filed: March 23, 1995
    Date of Patent: July 8, 1997
    Assignee: Isis Pharmceuticals, Inc.
    Inventor: Daniel Peter Claude McGee